Results 221 to 230 of about 24,275 (247)
Some of the next articles are maybe not open access.

Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators

ChemMedChem, 2018
AbstractSelective optimization of side activities (SOSA) offers an alternative entry to early drug discovery and may provide rapid access to bioactive new chemical entities with desirable properties. SOSA aims to reverse a drug's side activities through structural modification and to design out the drug's original main action.
Simone Schierle   +3 more
openaire   +2 more sources

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

Drug Discovery Today, 2012
Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent chronic liver condition evolving in a proportion of patients into nonalcoholic steatohepatitis (NASH), an aggressive form of NAFLD associated with increased cardiovascular mortality and significant risk of progressive liver disease, including fibrosis, cirrhosis and hepatocellular carcinoma.
Luciano, Adorini   +2 more
openaire   +2 more sources

The role of the farnesoid X receptor in diabetes and its complications

Molecular and Cellular Biochemistry
Diabetes is a metabolic disease in which tissues and organs are exposed to a hyperglycemic environment for a prolonged period. Long-term hyperglycemia can cause dysfunction of multiple organs and tissues in the body, leading to diabetic complications such as diabetic cardiomyopathy and diabetic nephropathy.
Shengnan, Zhang   +5 more
openaire   +2 more sources

Bile Acids and Farnesoid X Receptor in Renal Pathophysiology

Nephron
Background: Bile acids (BAs) act not only as lipids and lipid-soluble vitamin detergents but also function as signaling molecules, participating in diverse physiological processes. The identification of BA receptors in organs beyond the enterohepatic system, such as the farnesoid X receptor (FXR), has initiated inquiries into their organ-specific ...
Yang, Jiufang   +2 more
openaire   +2 more sources

The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease

Expert Opinion on Drug Discovery, 2021
Stefano Fiorucci   +2 more
exaly  

Home - About - Disclaimer - Privacy